Revenue ₹721 Cr (+6% YoY)
Promise tracking available after 2+ quarters of coverage.
View all executive profiles for Aarti Drugs LimitedAarti Drugs reported Q4 FY26 consolidated revenue of ₹721.1 crore (+6% YoY) and EBITDA of ₹96.6 crore (13.4% margin).
Quarterly Earnings Timeline
Financial verification status, call summary, sentiment, and management-delivery signals by quarter.
Q4 FY26
30 Apr 2026
Revenue ₹721 Cr (+6% YoY)
Aarti Drugs reported Q4 FY26 consolidated revenue of ₹721.1 crore (+6% YoY) and EBITDA of ₹96.6 crore (13.4% margin).
neutral
medium
Scorecard starts after historical backfill
Read full analysis →
Q3 FY26
10 Feb 2026
Revenue ₹603 Cr (+8.2% YoY)
Aarti Drugs reported a mixed Q3 FY26 with consolidated revenue of ₹602.9 crore (+8% YoY) but EBITDA margin contracting to 9.3% (-180bps YoY) due to low capacity utiliz...
neutral
medium
Scorecard starts after historical backfill
Read full analysis →
Q2 FY26
06 Nov 2025
Revenue ₹653 Cr (+9% YoY)
Aarti Drugs reported a solid Q2 FY26 with consolidated revenue of ₹652.9 crore (+9% YoY) and EBITDA of ₹84.4 crore (+23% YoY), driven by robust export volume growth of...
bullish
high
Scorecard starts after historical backfill
Read full analysis →